169 related articles for article (PubMed ID: 17984667)
1. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW
J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667
[TBL] [Abstract][Full Text] [Related]
2. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
[TBL] [Abstract][Full Text] [Related]
3. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
[TBL] [Abstract][Full Text] [Related]
5. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Fliser D; Buchholz K; Haller H;
Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
[TBL] [Abstract][Full Text] [Related]
6. Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Kanno H; Iwai M; Inaba S; Senba I; Nakaoka H; Sone H; Mogi M; Horiuchi M
Hypertens Res; 2009 Aug; 32(8):706-11. PubMed ID: 19478815
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance.
Chen M; Ichiki T; Ohtsubo H; Imayama I; Inanaga K; Miyazaki R; Sunagawa K
Hypertens Res; 2007 Oct; 30(10):971-8. PubMed ID: 18049030
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
Mizukawa M; Ohmori K; Obayashi A; Ishihara Y; Yoshida J; Noma T; Yukiiri K; Kosaka H; Kohno M
Hypertens Res; 2009 Jul; 32(7):617-24. PubMed ID: 19461650
[TBL] [Abstract][Full Text] [Related]
9. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Kühnast S; van der Hoorn JW; van den Hoek AM; Havekes LM; Liau G; Jukema JW; Princen HM
J Hypertens; 2012 Jan; 30(1):107-16. PubMed ID: 22134386
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.
Arishiro K; Hoshiga M; Negoro N; Jin D; Takai S; Miyazaki M; Ishihara T; Hanafusa T
J Am Coll Cardiol; 2007 Apr; 49(13):1482-9. PubMed ID: 17397679
[TBL] [Abstract][Full Text] [Related]
12. 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages.
Pols TW; Bonta PI; Pires NM; Otermin I; Vos M; de Vries MR; van Eijk M; Roelofsen J; Havekes LM; Quax PH; van Kuilenburg AB; de Waard V; Pannekoek H; de Vries CJ
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1591-7. PubMed ID: 20413732
[TBL] [Abstract][Full Text] [Related]
13. Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.
Kimura N; Shimizu H; Eldawoody H; Nakayama T; Saito A; Tominaga T; Takahashi A
Brain Res; 2010 Mar; 1322():144-52. PubMed ID: 20114040
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
Lorenzen JM; Neunhöffer H; David S; Kielstein JT; Haller H; Fliser D
Atherosclerosis; 2010 Mar; 209(1):184-8. PubMed ID: 19801149
[TBL] [Abstract][Full Text] [Related]
15. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.
Yamamoto E; Yamashita T; Tanaka T; Kataoka K; Tokutomi Y; Lai ZF; Dong YF; Matsuba S; Ogawa H; Kim-Mitsuyama S
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):556-63. PubMed ID: 17170375
[TBL] [Abstract][Full Text] [Related]
16. Functional effects of eggs, naturally enriched with conjugated linoleic acid, on the blood lipid profile, development of atherosclerosis and composition of atherosclerotic plaque in apolipoprotein E and low-density lipoprotein receptor double-knockout mice (apoE/LDLR-/-).
Franczyk-Zarów M; Kostogrys RB; Szymczyk B; Jawień J; Gajda M; Cichocki T; Wojnar L; Chlopicki S; Pisulewski PM
Br J Nutr; 2008 Jan; 99(1):49-58. PubMed ID: 17678565
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
Kitamoto S; Nakano K; Hirouchi Y; Kohjimoto Y; Kitajima S; Usui M; Inoue S; Egashira K
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1522-8. PubMed ID: 15178560
[TBL] [Abstract][Full Text] [Related]
18. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertens Res; 2008 Jun; 31(6):1199-208. PubMed ID: 18716369
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
